GMXAY
GENMAB A/S/S ADR

51
Loading...
Loading...
News
all
press releases
News Placeholder
Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal
The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.
Stocktwits·10d ago
News Placeholder
Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race
Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.
Stocktwits·11d ago

Latest GMXAY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.